Physician profile
Ananth Mudgil
NPI 1821190877
$3,657.89
in general payments reported to CMS, 2019-2025
28 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $248 · 2021: $672 · 2022: $768 · 2023: $453 · 2024: $259 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,081.05 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Horizon Therapeutics Plc | $707.88 | 2021-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $282.61 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Allergan, INC. | $223.30 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $222.83 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $197.16 | 2019-2023 | Cequa |
| Abbvie INC. | $95.97 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $94.04 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $90.23 | 2022-2024 | Xiidra, Miebo |
| Oyster Point Pharma, INC. | $76.85 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $71.38 | 2019-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $66.34 | 2019-2021 | |
| Biotissue Holdings INC. | $61.66 | 2021-2025 | |
| Omeros Corporation | $61.41 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $49.98 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.79 | 2021 | |
| Dompe US, INC. | $29.48 | 2025 | Oxervate |
| Travere Therapeutics, INC. | $28.67 | 2019-2021 | |
| Coopervision INC. | $26.94 | 2025 | Misight Contact Lens |
| Thea Pharma INC. | $20.96 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.27 | 2024 | Vevye |
| Amgen INC. | $18.04 | 2024 | Tepezza |
| Beaver-Visitec International, INC. | $17.85 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Rayner Intraocular Lenses Limited | $16.94 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Eyevance Pharmaceuticals LLC | $16.18 | 2022 | |
| Maculogix, INC. | $8.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Mudgil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.